Zevra Therapeutics's top three insider shareholders as of April 17, 2026 are Neil F. Mcfarlane (President And Ceo, 387.23K shares), R. Laduane Clifton (Cfo Treasurer, 143.51K shares), John B Bode (Director, 123.40K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Neil F. Mcfarlane | President And Ceo | 387,225 | 0 | 10 Feb, 2026 |
| R. Laduane Clifton | Cfo Treasurer | 143,515 | 0 | 07 Jan, 2026 |
| John B Bode | - | 123,400 | 0 | 26 Mar, 2026 |
| Travis C Mickle | President Ceo | 0 | 96,153 | 24 Aug, 2021 |
| Joshua Schafer | Cco | 62,278 | 0 | 04 Feb, 2026 |
| Travis C Mickle | President Ceo | 39,521 | 11,034 | 25 May, 2022 |
| Rahsaan Thompson | Chief Legal Compliance | 49,919 | 0 | 02 Feb, 2026 |
| Richard W Pascoe | Chief Executive Officer | 29,973 | 0 | 13 Mar, 2023 |
| Timothy J. Sangiovanni | Svp, Finance Corp Controller | 29,590 | 0 | 04 Feb, 2026 |
| Alvin Shih | - | 20,000 | 0 | 15 Sep, 2025 |
| Thomas Anderson | - | 20,000 | 0 | 16 Jul, 2024 |
| Richard W Pascoe | Chief Executive Officer | 19,973 | 0 | 13 Jan, 2023 |
| Matthew R Plooster | - | 18,500 | 0 | 13 Mar, 2023 |
| David S Tierney | - | 10,835 | 0 | 13 Mar, 2023 |
| Adrian W Quartel | Chief Medical Officer | 9,723 | 0 | 02 Feb, 2026 |
| Matthew R Plooster | - | 7,500 | 0 | 18 May, 2022 |
| Tamara A Favorito | - | 3,894 | 0 | 16 Sep, 2025 |
| Corey Michael Watton | - | 1,800 | 0 | 31 Mar, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 24 Mar, 2026 | John B Bode | Common Stock | A | 39,200 | $4.97 | 84,200 | D | M |
| 24 Mar, 2026 | John B Bode | Common Stock | A | 39,200 | $4.89 | 123,400 | D | M |
| 24 Mar, 2026 | John B Bode | Stock Option (right to buy) | D | 39,200 | $0.00 | 19,600 | D | M |
| 24 Mar, 2026 | John B Bode | Stock Option (right to buy) | D | 39,200 | $0.00 | 0 | D | M |
| 18 Mar, 2026 | Justin A Renz | Stock Option (right to buy) | A | 300,000 | $0.00 | 300,000 | D | A |
| 07 Feb, 2026 | Neil F. Mcfarlane | Common Stock | A | 37,500 | - | 401,850 | D | M |
| 09 Feb, 2026 | Neil F. Mcfarlane | Common Stock | D | 14,625 | $8.56 | 387,225 | D | S |
| 07 Feb, 2026 | Neil F. Mcfarlane | Restricted Stock Unit | D | 37,500 | $0.00 | 75,000 | D | M |
| 03 Feb, 2026 | Timothy J. Sangiovanni | Common Stock | D | 3,000 | $9.18 | 29,590 | D | S |
| 03 Feb, 2026 | Joshua Schafer | Common Stock | D | 10,500 | $9.19 | 62,278 | D | S |
| 30 Jan, 2026 | Joshua Schafer | Common Stock | A | 11,333 | - | 40,819 | D | M |
| 31 Jan, 2026 | Neil F. Mcfarlane | Common Stock | A | 233,334 | - | 455,350 | D | M |
| 30 Jan, 2026 | Adrian W Quartel | Common Stock | A | 11,333 | - | 14,256 | D | M |
| 30 Jan, 2026 | Rahsaan Thompson | Common Stock | A | 11,333 | - | 53,999 | D | M |
| 30 Jan, 2026 | Timothy J. Sangiovanni | Common Stock | A | 6,333 | - | 22,674 | D | M |
| 30 Jan, 2026 | Joshua Schafer | Common Stock | D | 3,375 | $8.83 | 37,444 | D | S |
| 30 Jan, 2026 | Timothy J. Sangiovanni | Common Stock | D | 1,750 | $8.82 | 20,924 | D | S |
| 30 Jan, 2026 | Adrian W Quartel | Common Stock | D | 4,533 | $8.83 | 9,723 | D | S |
| 02 Feb, 2026 | Neil F. Mcfarlane | Common Stock | D | 91,000 | $9.38 | 364,350 | D | S |
| 30 Jan, 2026 | Rahsaan Thompson | Common Stock | D | 4,080 | $8.83 | 49,919 | D | S |